Roquinimex is an immunomodulator with diverse biological activities. In vivo, roquinimex (80 mg/kg) increases the number of myocardial MHC class II-expressing cells, the ratio of cytotoxic to helper T cells, and survival and decreases necrotic lesion area in a mouse model of murine coxsackievirus B3-induced myocarditis. It induces IFN-γ production, reduces TNF-α and IL-1β production, prevents the development of proteinuria, and ameliorates nephritis in a mouse model of chronic graft versus host disease (GVHD). Roquinimex (300 mg/kg) decreases colonic myeloperoxidase (MPO) activity and mucosal damage in a mouse model of colitis induced by dextran sulfate (DSS; ). It also decreases tumor weight and tumor blood flow in a von Hippel-Lindau (VHL) type 2a paraganglioma mouse xenograft model.
An immunomodulator with antitumour properties. Inhibits T-cell apoptosis in vivo; also inhibits angiogenesis in rats
Biological response modifier; immunomodulator.
ChEBI: 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide is an aromatic amide.
Immunomodulator with stimulatory and antitumor properties. Inhibits in vivo apoptosis of T-cells and inhibits angiogenesis in rats in vivo .
